The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Isoform-selective histone deacetylase inhibitors
Open accessAbstract
Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes. This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors. The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylases (HDACs) are epigenetic regulators that modulate gene expression by removing acetyl groups from lysine residues on proteins, affecting processes like cell proliferation, differentiation, and development.504,505”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [504]
Citations
Cites
Epigenetic programming by maternal behavior
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., & Meaney, M. J. (2004) · Nature Neuroscience · doi:10.1038/nn1276 · Cited by 6,177
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
(2002) · PubMed · Cited by 732
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638
Kinetic and Catalytic Mechanisms of Protein Kinases
Adams, J. A. (2001) · Chemical Reviews · doi:10.1021/cr000230w · Cited by 627
Grozinger, C. M., & Schreiber, S. L. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00092-3 · Cited by 537
Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
Gurvich, N., Tsygankova, O. M., Meinkoth, J. L., & Klein, P. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0799 · Cited by 459
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
Grant, S., Easley, C., & Kirkpatrick, P. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2227 · Cited by 412
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Increased expression of histone deacetylase 2 is found in human gastric cancer
SONG, J., NOH, J. H., LEE, J. H., EUN, J. W., AHN, Y. M., KIM, S. Y., LEE, S. H., PARK, W. S., YOO, N. J., LEE, J. Y., et al. (2005) · APMIS · doi:10.1111/j.1600-0463.2005.apm_04.x · Cited by 346
25 years after the nucleosome model: chromatin modifications
Wu, J. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01718-7 · Cited by 342
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Saji, S., Kawakami, M., Hayashi, S.-I., Yoshida, N., Hirose, M., Horiguchi, S.-I., Itoh, A., Funata, N., Schreiber, S. L., Yoshida, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208646 · Cited by 258
Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
Guardiola, A. R., & Yao, T.-P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109861200 · Cited by 253
Wang, D.-F., Helquist, P., Wiech, N. L., & Wiest, O. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0505011 · Cited by 208
Haggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A., & Schreiber, S. L. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00095-4 · Cited by 201
Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., & Sanders, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22751 · Cited by 192
Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 192
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., & Brosch, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049002a · Cited by 184
Moradei, O. M., Mallais, T. C., Frechette, S., Paquin, I., Tessier, P. E., Leit, S. M., Fournel, M., Bonfils, C., Trachy-Bourget, M.-C., Liu, J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701079h · Cited by 166
Crystal Structure of a Bacterial Class 2 Histone Deacetylase Homologue
Nielsen, T. K., Hildmann, C., Dickmanns, A., Schwienhorst, A., & Ficner, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.065 · Cited by 158
Wang, D., Wiest, O., Helquist, P. M., Lan-Hargest, H.-Y., & Wiech, N. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0498497 · Cited by 145
Park, J., Jung, Y., Kim, T. Y., Kim, S. G., Jong, H.-S., Lee, S. E., Kim, D.-K., Lee, J., Kim, N. K., Kim, T., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0709 · Cited by 143
Kornberg, R. D., & Klug, A. (1981) · Scientific American · doi:10.1038/scientificamerican0281-52 · Cited by 128
Subtype Selective Substrates for Histone Deacetylases
Heltweg, B., Dequiedt, F., Marshall, B. L., Brauch, C., Yoshida, M., Nishino, N., Verdin, E. M., & Jung, M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0497592 · Cited by 125
Bartling, B., Hofmann, H., Boettger, T., Hansen, G., Burdach, S. E. G., Silber, R., & Simm, A. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.02.006 · Cited by 123
Gopal, Y. N. V., Arora, T. S., & Dyke, M. W. V. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.06.007 · Cited by 120
Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity
Wong, J. C., Hong, R., & Schreiber, S. L. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0341440 · Cited by 115
Itoh, Y., Suzuki, T., Kouketsu, A., Suzuki, N., Maeda, S., Yoshida, M., Nakagawa, H., & Miyata, N. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm7009217 · Cited by 112
Khabele, D., Son, D., Parl, A. K., Goldberg, G. L., Augenlicht, L. H., Mariadason, J. M., & Rice, V. M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.5.4007 · Cited by 111
Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M., Nakagawa, H., & Miyata, N. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060554y · Cited by 107
Arts, J., Angibaud, P. R., Mariën, A., Floren, W., Janssens, B., King, P., Dun, J. V., Janssen, L., Geerts, T., Tuman, R. W., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604025 · Cited by 96
HDAC inhibitors overcome first hurdle
Garber, K. (2007) · Nature Biotechnology · doi:10.1038/nbt0107-17 · Cited by 94
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93
Yurek‐George, A., Cecil, A., Mo, A. H. K., Wen, S., Rogers, H., Habens, F., Maeda, S., Yoshida, M., Packham, G., & Ganesan, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0703800 · Cited by 85
Molecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity
Maulucci, N., Chini, M. G., Micco, S. D., Izzo, I., Cafaro, E., Russo, A., Gallinari, P., Paolini, C., Nardi, M. C., Casapullo, A., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0686256 · Cited by 85
Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases
Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R., et al. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.01.030 · Cited by 80
Bouchain, G., & Delorme, D. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456585 · Cited by 80
Schäfer, S., Saunders, L. R., Eliseeva, E. D., Velena, A., Jung, M., Schwienhorst, A., Strasser, A., Dickmanns, A., Ficner, R., Schlimme, S., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.092 · Cited by 71
A series of novel, potent, and selective histone deacetylase inhibitors
JONES, P. G., Altamura, S., Chakravarty, P. K., Cecchetti, O., Francesco, R. D., Gallinari, P., Ingenito, R., Meinke, P. T., Petrocchi, A., Rowley, M., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.002 · Cited by 68
Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylases
Nishino, N., Jose, B., Okamura, S., Ebisusaki, S., Kato, T., Sumida, Y., & Yoshida, M. (2003) · Organic Letters · doi:10.1021/ol036098e · Cited by 67
Mai, A., Massa, S., Pezzi, R., Rotili, D., Loidl, P., & Brosch, G. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034167p · Cited by 65
Shinji, C., Maeda, S., Imai, K., Yoshida, M., Hashimoto, Y., & Miyachi, H. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.07.008 · Cited by 57
Bispyridinium Dienes: Histone Deacetylase Inhibitors with Selective Activities
Pérez‐Balado, C., Nebbioso, A., Rodríguez‐Graña, P., Minichiello, A., Miceli, M., Altucci, L., & de Lera, Á. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070028m · Cited by 53
Bhuiyan, M. P. I., Kato, T., Okauchi, T., Nishino, N., Maeda, S., Nishino, T. G., & Yoshida, M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.063 · Cited by 50
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors
Hamblett, C. L., Methot, J. L., Mampreian, D. M., Sloman, D. L., Stanton, M. G., Kral, A. M., Fleming, J. C., Cruz, J. C., Chénard, M., Ozerova, N. D. S., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.023 · Cited by 49
Expression and functional characterization of recombinant human HDAC1 and HDAC3
Li, J., Staver, M. J., Curtin, M. L., Holms, J. H., Frey, R. R., Edalji, R. P., Smith, R. A., Michaelides, M. R., Davidsen, S. K., & Glaser, K. B. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.070 · Cited by 49
Design and Synthesis of a Potent Histone Deacetylase Inhibitor
Liu, T., Kapustin, G. V., & Etzkorn, F. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061082q · Cited by 42
Design of novel histone deacetylase inhibitors
Siliphaivanh, P., Harrington, P., Witter, D. J., Otte, K. M., Tempest, P. A., Kattar, S. D., Kral, A. M., Fleming, J. C., Deshmukh, S. V., Harsch, A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.080 · Cited by 42
Research works printed but not linked: 1
- Furumai, 2002, Cancer Res., 62, 4916
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“504,505 Among them, HDAC6 has two catalytic domains and a C-terminal zinc fi nger domain, interacts with tau and α -tubulin, and is involved in the degradation of protein aggregates, mitochondrial transport, and cognitive memory, 506 – 509 making it relevant to AD pathology.”
BackgroundEpigenetic Modifications: Basic Mechanisms and Role in Cardiovascular Disease
Handy, D. E., Castro, R., & Loscalzo, J. (2011) · Circulation · doi:10.1161/circulationaha.110.956839 · Cited by 1,067
Short-chain fatty acids in diseases
Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., & Xu, Z.-X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01219-9 · Cited by 718
Bowers, E. M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M. A., Crump, N. T., Hazzalin, C. A., Liszczak, G., Yuan, H., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.006 · Cited by 666
Epigenetics: a molecular link between environmental factors and type 2 diabetes
Ling, C., & Groop, L. (2009) · Diabetes · doi:10.2337/db09-1003 · Cited by 617
“, HDAC inhibitors, can be used in the treatment of diabetic complications (13,111,112).”
Background
Metadata
- Authors
- Bieliauskas, A. V., & Pflum, M. K. H.
- Affiliations
- Wayne State University (US)
- Corresponding author
- Pflum, Mary Kay H.
- ORCID
- Pflum, Mary Kay H.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2008
- Volume
- 37
- Issue
- 7
- Pages
- 1402
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- PMC
- PMC2593472
- OpenAlex
- W2124258829
- Cited by
- 350
- References
- 59
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 10 · 2021: 12 · 2020: 21 · 2019: 20 · 2018: 19 · 2017: 16 · 2016: 21 · 2015: 21 · 2014: 27 · 2013: 22 · 2012: 22
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (GM 067657, R01GM067657)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- histone deacetylase inhibitors, HDAC isoforms, isoform selectivity, cancer therapy, small molecule inhibitors, transcriptional regulation
- MeSH terms
- Vorinostat, Antineoplastic Agents, Binding Sites, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Tumor Cells, Cultured, Drug Design, Protein Isoforms, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.